# Faslodex in McCune-Albright Syndrome

> **NCT00278915** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Puberty, Precocious
- McCune-Albright Syndrome

## Interventions

- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT00278915
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01-31
- **Primary completion:** 2009-12-08
- **Final completion:** 2023-07-20
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278915, "Faslodex in McCune-Albright Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00278915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*